Nomura Holdings
CASC

Nomura Holdings’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Nomura Holdings’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,150
Closed -$522K – 2129
2015
Q2 		$522K Buy
+23,150
New +$366K ﹤0.01% 1246
2015
Q1 		– Sell
-26,764
Closed -$303K – 2504
2014
Q4 		$303K Sell
26,764
-5,258
-16% -$57.1K ﹤0.01% 1900
2014
Q3 		$370K Buy
32,022
+19,995
+166% +$305K ﹤0.01% 2034
2014
Q2 		$230K Buy
12,027
+897
+8% +$15.8K ﹤0.01% 2302
2014
Q1 		$205K Buy
11,130
+9,211
+480% +$151K ﹤0.01% 2325
2013
Q4 		$20K Sell
1,919
-4,250
-69% -$47.5K ﹤0.01% 1928
2013
Q3 		$76K Sell
6,169
-5,328
-46% -$56.1K ﹤0.01% 2095
2013
Q2 		$111K Buy
+11,497
New +$148K ﹤0.01% 1978

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nomura Holdings's CASC Position: Q3 2015 in Review

Nomura Holdings sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 23,150 shares — an estimated $522K sold.

Nomura Holdings first reported a position in CASC in Q2 2013 and held it in 8 quarters. The position peaked at $522K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • Nomura Holdings reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Nomura Holdings sold 23,150 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $522K.
  • Nomura Holdings first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
  • Nomura Holdings's Cascadian Therapeutics, Inc. position peaked at $522K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Nomura Holdings's 13F filing for Q3 2015, filed 16 Nov 2015.